A study to evaluate efficacy of single dose Benralizumab (Fasenra) treatment for difficult-to-treat adult asthma
Latest Information Update: 31 Oct 2018
Price :
$35 *
At a glance
- Drugs Benralizumab (Primary)
- Indications Aspirin-induced asthma
- Focus Therapeutic Use
- 25 Oct 2018 Status changed from not yet recruiting to discontinued.
- 03 May 2018 New trial record